Tags

Type your tag names separated by a space and hit enter

Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval.
Viruses. 2020 Dec 31; 13(1)V

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is transmitted primarily through respiratory droplets/aerosols and it causes COVID-19. The virus infects epithelial cells by using the spike protein on its surface to bind to angiotensin-converting enzyme 2 receptor on the cells. Thus, candidate vaccines targeting the spike protein are currently being developed to prevent against infections. Approximately 44 SARS-CoV-2 candidate vaccines are in clinical trials (phase I-III) and an additional 164 candidates are in preclinical stages. The efficacy data from phase I/II trials of lead candidate vaccines look very promising with virus-neutralizing geometric mean antibody titers in the range of 16.6-3906. Most recently, two SARS-CoV-2 candidate vaccines, BNT162b2 and mRNA-1273, have been granted the first emergency use authorization (EUA) in the U.S.; BNT162b2 has also been granted an EUA in the United Kingdom, Canada, and in the European Union. This review assesses whether SARS-CoV-2 candidate vaccines (with approved EUA or in phase III trials) meet the criteria for an ideal SARS-CoV-2 vaccine. The review concludes with expectations from phase III trials and recommendations for phase IV studies (post-vaccine approval).

Authors+Show Affiliations

Texas Tech University School of Veterinary Medicine, Amarillo, TX 79106, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

33396343

Citation

Tumban, Ebenezer. "Lead SARS-CoV-2 Candidate Vaccines: Expectations From Phase III Trials and Recommendations Post-Vaccine Approval." Viruses, vol. 13, no. 1, 2020.
Tumban E. Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval. Viruses. 2020;13(1).
Tumban, E. (2020). Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval. Viruses, 13(1). https://doi.org/10.3390/v13010054
Tumban E. Lead SARS-CoV-2 Candidate Vaccines: Expectations From Phase III Trials and Recommendations Post-Vaccine Approval. Viruses. 2020 Dec 31;13(1) PubMed PMID: 33396343.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval. A1 - Tumban,Ebenezer, Y1 - 2020/12/31/ PY - 2020/12/08/received PY - 2020/12/27/revised PY - 2020/12/29/accepted PY - 2021/1/5/entrez PY - 2021/1/6/pubmed PY - 2021/1/20/medline KW - COVID-19 KW - SARS-CoV-2 KW - SARS-CoV-2 vaccines KW - clinical trials JF - Viruses JO - Viruses VL - 13 IS - 1 N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is transmitted primarily through respiratory droplets/aerosols and it causes COVID-19. The virus infects epithelial cells by using the spike protein on its surface to bind to angiotensin-converting enzyme 2 receptor on the cells. Thus, candidate vaccines targeting the spike protein are currently being developed to prevent against infections. Approximately 44 SARS-CoV-2 candidate vaccines are in clinical trials (phase I-III) and an additional 164 candidates are in preclinical stages. The efficacy data from phase I/II trials of lead candidate vaccines look very promising with virus-neutralizing geometric mean antibody titers in the range of 16.6-3906. Most recently, two SARS-CoV-2 candidate vaccines, BNT162b2 and mRNA-1273, have been granted the first emergency use authorization (EUA) in the U.S.; BNT162b2 has also been granted an EUA in the United Kingdom, Canada, and in the European Union. This review assesses whether SARS-CoV-2 candidate vaccines (with approved EUA or in phase III trials) meet the criteria for an ideal SARS-CoV-2 vaccine. The review concludes with expectations from phase III trials and recommendations for phase IV studies (post-vaccine approval). SN - 1999-4915 UR - https://www.unboundmedicine.com/medline/citation/33396343/Lead_SARS_CoV_2_Candidate_Vaccines:_Expectations_from_Phase_III_Trials_and_Recommendations_Post_Vaccine_Approval_ L2 - https://www.mdpi.com/resolver?pii=v13010054 DB - PRIME DP - Unbound Medicine ER -